Spiriva® Assessment of FEV1 (SAFE). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Long-term Treatment in Patients With COPD. A One-year Parallel Group, Double-blind, Randomised, Placebo-controlled Study
收藏DataCite Commons2025-12-08 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003454/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this trial is to evaluate whether the effect of one year (48 weeks) treatment with inhaled tiotropium bromide (Spiriva® - 18 µg once daily) on the change in trough FEV1, compared to placebo in patients with COPD, is affected by smoking status.
提供机构：
Vivli
创建时间：
2019-04-12
